The proportions of elderly patients in all cancers have been rising steadily and the trend is expected to continue. Lung cancer causes more deaths than the next four leading causes of cancer deaths combined. Patients older than 70 years constitute 47% of all lung cancer patients at the time of diagnosis. Significant proportions of elderly lung patients are excluded from either curative or life-extending therapy and elderly lung patients are less likely to participate in clinical trials. The research community has recommended enrolling more elderly lung patients in clinical trials, including trials specifically designed for them, and further investigation to define the """"""""fit"""""""" and """"""""frail"""""""" elderly patient populations. As a prelude to such trials, there is a need to improve our understanding of the current status of elderly lung cancer patients and the potential risks and benefits associated with chemotherapy and radiation. We will assemble data from existing phase II/III trials in the period 1990-2010 for non-small cell and small cell lung cancer from six national cancer cooperative groups to evaluate the benefits and risks of treating elderly lung cancer patients with radiation and chemotherapy. In comparison to their younger counterparts, the pooled analysis on the cooperative group data offers an opportunity to evaluate patient characteristics and clinical outcomes of the elderly patients as well as the benefits and risks of chemotherapy and radiation. Recognizing that the population of elderly lung cancer patients is a heterogeneous population, which can be classified into several subgroups based on their clinical profiles, we will develop and validate an Elderly Prognostic Index (EPI) to optimize treatment strategies and aid the assignment of elderly patients to therapies. The primary goal of this research is to perform pooled analyses of clinical studies from multi-center cooperative groups to address questions specific to elderly patients.
We aim to characterize the current status of elderly lung cancer patients who participated in cooperative group trials, to compare efficacy and toxicity between treatment strategies, to apply novel statistical tools for pooled analysis, to establish an accurate and reproducible prognostic index for treatment assignments, and to assess and control the impact of potential imbalance of baseline covariates using casual inference methods. The results of this project will help design and implement future elderly- specific trials. Specifi Aim 1: Using elderly lung cancer data aggregated from hundreds of clinical trials, we compare 1a) efficacy and toxicity of sequential chemotherapy and radiation vs. concurrent chemoradiotherapy in locally advanced Non-Small Cell Lung Cancer;and 1b) the efficacy and toxicity of platinum vs. non-platinum-based therapy in extensive and limited Small Cell Lung Cancer patients with different baseline characteristics.
Specific Aim 2 : We will 2a) build the EPI, a predictive model that helps assign elderly patients in elderly-specific trials;and 2b) utilize statistical methods for causal inference to evaluate and control the impact of imbalanced baseline covariates.

Public Health Relevance

While more than half of lung cancer patients are elderly, the elderly patients have been less studied and are more likely to be suboptimally treated than their younger counterparts. This project will provide information regarding efficacy and toxicity of several treatment strategies and help resolve important issues regarding the management of elderly patients with lung cancer. Our research is expected to have significant impact on existing clinical practice and the design of elderly-specific lung cancer clinical trials.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Zieman, Susan
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Biostatistics & Other Math Sci
Schools of Medicine
United States
Zip Code
Wang, Xiaofei; Zhou, Jingzhu; Wang, Ting et al. (2018) On Enrichment Strategies for Biomarker Stratified Clinical Trials. J Biopharm Stat 28:292-308
Stinchcombe, Thomas E; Fan, Wen; Schild, Steven E et al. (2018) A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer :
Wang, Ting; Wang, Xiaofei; Zhou, Haibo et al. (2018) Auxiliary variable-enriched biomarker-stratified design. Stat Med 37:4610-4635
Schild, Steven E; Fan, Wen; Stinchcombe, Thomas E et al. (2018) Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. J Thorac Oncol :
Wang, Xiaofei; Wang, Xiaoyi; Hodgson, Lydia et al. (2017) Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. Oncologist 22:189-198
Yao, Xiaoxin I; Wang, Xiaofei; Speicher, Paul J et al. (2017) Reporting and Guidelines in Propensity Score Analysis: A Systematic Review of Cancer and Cancer Surgical Studies. J Natl Cancer Inst 109:
Stinchcombe, Thomas E; Zhang, Ying; Vokes, Everett E et al. (2017) Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol 35:2885-2892
Pang, Herbert; Wang, Xiaofei (2016) Statistical aspect of translational and correlative studies in clinical trials. Chin Clin Oncol 5:11
Pang, Herbert H; Wang, Xiaofei; Stinchcombe, Thomas E et al. (2016) Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. J Clin Oncol 34:3992-3999
Wang, Xiaofei; Berry, Mark F (2016) Risk calculators are useful but.... J Thorac Cardiovasc Surg 151:706-707

Showing the most recent 10 out of 12 publications